ALDH1A2 (Aldehyde Dehydrogenase 1 Family Member A2)

ALDH1A2 (Aldehyde Dehydrogenase 1 Family Member A2)

Introduction

ALDH1A2, also known as Retinaldehyde Dehydrogenase 2 (RALDH2), is a crucial enzyme in the retinoic acid biosynthesis pathway. This gene encodes a member of the aldehyde dehydrogenase family that catalyzes the oxidation of retinaldehyde (retinal) to retinoic acid (RA), the biologically active form of vitamin A. Retinoic acid serves as a critical signaling molecule in embryonic development, tissue patterning, and cellular differentiation, particularly in the developing and mature [central nervous system](/brain-regions/central-nervous-system).

The role of ALDH1A2 in [Parkinson's disease](/diseases/parkinsons-disease) and other neurodegenerative disorders has garnered significant research attention in recent years. The enzyme's function in dopaminergic neuron development, survival, and function makes it a potential therapeutic target for neurodegenerative conditions affecting the [substantia nigra](/brain-regions/substantia-nigra) and basal ganglia circuits.

ALDH1A2 (Aldehyde Dehydrogenase 1 Family Member A2)

Introduction

ALDH1A2, also known as Retinaldehyde Dehydrogenase 2 (RALDH2), is a crucial enzyme in the retinoic acid biosynthesis pathway. This gene encodes a member of the aldehyde dehydrogenase family that catalyzes the oxidation of retinaldehyde (retinal) to retinoic acid (RA), the biologically active form of vitamin A. Retinoic acid serves as a critical signaling molecule in embryonic development, tissue patterning, and cellular differentiation, particularly in the developing and mature [central nervous system](/brain-regions/central-nervous-system).

The role of ALDH1A2 in [Parkinson's disease](/diseases/parkinsons-disease) and other neurodegenerative disorders has garnered significant research attention in recent years. The enzyme's function in dopaminergic neuron development, survival, and function makes it a potential therapeutic target for neurodegenerative conditions affecting the [substantia nigra](/brain-regions/substantia-nigra) and basal ganglia circuits.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">ALDH1A2 Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ALDH1A2</td></tr>
<tr><td><strong>Full Name</strong></td><td>Aldehyde Dehydrogenase 1 Family Member A2</td></tr>
<tr><td><strong>Alternative Names</strong></td><td>RALDH2, RALDH2, ALDH1A2, ALDH-E2</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>15q21.2</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>8854</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000128918</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>O00469</td></tr>
<tr><td><strong>OMIM</strong></td><td>603687</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers-disease), Retinitis Pigmentosa, Neurodegeneration</td></tr>
</table>
</div>

Gene Structure and Protein Architecture

Genomic Organization

The ALDH1A2 gene spans approximately 34.5 kb on the long arm of chromosome 15 (15q21.2) and consists of 14 exons encoding a 493-amino acid protein. The gene promoter contains multiple regulatory elements including:

• Retinoic acid response elements (RAREs) — Direct retinoic acid-mediated transcriptional regulation
• Vitamin D response elements (VDREs) — Cross-talk with vitamin D signaling
• AP-1 binding sites — Response to growth factors and cytokines
• CRE elements — cAMP-mediated regulation

Protein Structure

Retinaldehyde Dehydrogenase 2 (RALDH2) is a homotetrameric enzyme with each subunit approximately 56 kDa. The protein adopts the characteristic aldehyde dehydrogenase fold:

| Domain | Residues | Function |
|--------|----------|----------|
| N-terminal domain | 1-150 | Tetramerization interface, NAD(P) binding |
| Catalytic domain | 151-400 | Active site, substrate binding |
| C-terminal domain | 401-493 | Structural stabilization |

The active site contains a catalytic cysteine (Cys302) that performs nucleophilic attack on the aldehyde substrate, converting retinal to retinoic acid. The enzyme has high specificity for 9-cis-retinal and all-trans-retinal, the physiological substrates in the retinoic acid biosynthesis pathway.

Function

Normal Cellular Function

ALDH1A2/RALDH2 serves as the primary enzyme responsible for the irreversible oxidation of retinaldehyde to retinoic acid in many tissues, particularly during embryonic development and in specific adult tissues including the brain.

Retinoic Acid Biosynthesis Pathway

Retinoic Acid Signaling

Retinoic acid functions as a ligand for nuclear receptor families:

The RAR/RXR heterodimer binds to retinoic acid response elements (RAREs) in the promoter regions of target genes, regulating transcription of genes involved in:

• Neuronal differentiation and specification
• Axon guidance and synaptogenesis
• Dopaminergic neuron development
• Antioxidant and neuroprotective gene expression

Expression Pattern

ALDH1A2 is expressed in multiple tissues with distinct patterns:

| Tissue | Expression Level | Functional Significance |
|--------|-----------------|------------------------|
| [Substantia Nigra](/brain-regions/substantia-nigra) | Moderate | Dopaminergic neuron maintenance |
| [Ventral Tegmental Area](/brain-regions/ventral-tegmental-area) | Moderate | Mesolimbic dopamine pathway |
| [Striatum](/brain-regions/striatum) | Low-Moderate | Modulation of dopaminergic signaling |
| [Cortex](/brain-regions/cortex) | Moderate | Cortical development and function |
| [Retina](/brain-regions/retina) | High | Photoreceptor differentiation |
| Liver | High | Systemic retinoic acid production |
| Kidney | Moderate | Local retinoic acid synthesis |

In the adult brain, ALDH1A2 expression is maintained in regions associated with neurogenesis and synaptic plasticity, suggesting ongoing roles in neuronal homeostasis and repair.

Retinoic Acid in Dopaminergic Neuron Development

During embryonic development, retinoic acid signaling is essential for the specification and differentiation of midbrain dopaminergic neurons:

Disease Associations

Parkinson's Disease

ALDH1A2 and retinoic acid signaling are implicated in [Parkinson's disease](/diseases/parkinsons-disease) through multiple mechanisms:

Genetic Associations

• Risk variants: Certain ALDH1A2 polymorphisms have been associated with altered PD risk in some populations
• Expression changes: ALDH1A2 expression is reduced in the substantia nigra of PD patients
• Regulatory variants: Non-coding variants may affect ALDH1A2 expression in dopaminergic neurons

Pathogenic Mechanisms

| Mechanism | Description | Evidence |
|-----------|-------------|----------|
| Dopamine synthesis | RA regulates tyrosine hydroxylase and aromatic L-amino acid decarboxylase | [Escott et al., 2018](https://pubmed.ncbi.nlm.nih.gov/30267348/) |
| Oxidative stress | RA activates antioxidant gene expression | [Wang et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31102713/) |
| Neuroinflammation | RA modulates microglial activation and cytokine production | [Liao et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30690112/) |
| Neuronal survival | RA promotes anti-apoptotic signaling in dopaminergic neurons | [Kim et al., 2020](https://pubmed.ncbi.nlm.nih.gov/33106893/) |

Therapeutic Implications

Retinoic acid and ALDH1A2-based therapeutic strategies for PD include:

Current preclinical studies show promise for retinoic acid-based approaches in protecting dopaminergic neurons and improving behavioral outcomes in PD models.

Alzheimer's Disease

ALDH1A2 dysfunction may contribute to [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis:

• Amyloid processing: Retinoic acid influences amyloid precursor protein (APP) processing
• Tau phosphorylation: RA signaling modulates tau kinases and phosphatases
• Neuronal survival: Reduced RA signaling may increase neuronal vulnerability
• Synaptic function: RA is critical for synaptic plasticity and memory formation

Retinitis Pigmentosa

ALDH1A2 mutations are associated with recessive retinitis pigmentosa, a progressive retinal degeneration characterized by:

• Photoreceptor cell death
• Tunnel vision
• Complete blindness in advanced stages

Neurodegeneration: Broader Context

Beyond PD and AD, ALDH1A2/retinoic acid dysregulation has been implicated in:

• Amyotrophic Lateral Sclerosis (ALS) — Motor neuron vulnerability
• Huntington's Disease — Striatal neuron dysfunction
• Multiple Sclerosis — Demyelination and axonal loss
• Stroke — Ischemic brain injury response

Mechanistic Pathways

Dopaminergic Neuroprotection Pathway

Neuroinflammation Modulation

Retinoic acid exerts anti-inflammatory effects in the brain:

Therapeutic Targeting

Retinoic Acid-Based Therapies

| Treatment | Mechanism | Status | Application |
|-----------|-----------|--------|-------------|
| All-trans-retinoic acid (ATRA) | RAR agonist | Preclinical | PD, AD |
| 9-cis-retinoic acid | RAR/RXR agonist | Preclinical | Neuroprotection |
| RAR-selective agonists | Targeted RA signaling | Investigational | Selective targeting |
| RALDH2 activators | Increase endogenous RA | Preclinical | Local delivery |

Challenges and Considerations

• Dose optimization — RA has narrow therapeutic window
• Delivery — Blood-brain barrier penetration limitations
• Side effects — Teratogenicity, mucocutaneous toxicity
• Specificity — Off-target effects of general RA treatment

Combination Approaches

RA-based therapies may be combined with:

• Dopamine replacement (levodopa)
• Neurotrophic factors (GDNF, BDNF)
• Antioxidants (coenzyme Q10, vitamin E)
• Anti-inflammatory agents

Animal Models

ALDH1A2 Knockout Mice

Mice with ALDH1A2 deletion exhibit:

• Embryonic lethality (severe developmental defects)
• Retinoic acid deficiency
• Abnormal dopaminergic neuron development
• Increased susceptibility to neurotoxins

Conditional Knockouts

Brain-specific ALDH1A2 knockout mice show:

• Reduced dopaminergic markers in substantia nigra
• Behavioral abnormalities
• Increased oxidative stress
• Enhanced vulnerability to MPTP

Transgenic Models

RALDH2 overexpressing mice demonstrate:

• Increased retinoic acid in the brain
• Enhanced dopaminergic neuron survival
• Resistance to neurotoxin-induced damage
• Improved behavioral performance

Key Publications

Cross-References

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Dopamine Biosynthesis Pathway](/mechanisms/dopamine-biosynthesis-pathway)
• [Retinoic Acid Signaling Pathway](/mechanisms/retinoic-acid-signaling-pathway)
• [Substantia Nigra](/brain-regions/substantia-nigra)
• [Tyrosine Hydroxylase](/proteins/th-protein)
• [Nurr1 (NR4A2) Gene](/genes/nr4a2)
• [Retinitis Pigmentosa](/diseases/retinitis-pigmentosa)
• [Neuroprotection Mechanisms](/mechanisms/neuroprotection-pathways)

See Also

• [Genes Index](/genes)
• [ALDH1A2 Protein](/proteins/aldh1a2-protein)
• Retinaldehyde Dehydrogenase 2
• Retinoic Acid Signaling
• Parkinson's Disease Genetics
• [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)
• [Neuroprotection](/mechanisms/neuroprotection)
• Vitamin A Metabolism
• Retinoid Therapy

Pathway Diagram

The following diagram shows the key molecular relationships involving ALDH1A2 (Aldehyde Dehydrogenase 1 Family Member A2) discovered through SciDEX knowledge graph analysis: